FIELD: biotechnology.
SUBSTANCE: disclosed is an anti-ANGPTL3 antibody or an antigen-binding fragment thereof. Also disclosed is a nucleic acid coding an anti-ANGPTL3 antibody or a fragment thereof, and a host cell containing said nucleic acid for expressing the anti-ANGPTL3 antibody or an antigen-binding fragment thereof. Invention also relates to use of the anti-ANGPTL3 antibody or its antigen-binding fragment in an immunoassay method for determining ANGPTL3 and in a method of treating a disease or disorder representing hypercholesterolemia, hyperlipidemia or atherosclerotic disease.
EFFECT: invention can find further application in therapy.
15 cl, 9 dwg, 13 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODIES AGAINST CD40 AND APPLICATION THEREOF | 2019 |
|
RU2778572C1 |
| ANTIBODY AGAINST LAG-3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR PHARMACEUTICAL APPLICATION | 2017 |
|
RU2757813C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| CONJUGATE OF TROP-2 ANTIBODY AND EXATECAN ANALOGUE AND MEDICAL USE THEREOF | 2021 |
|
RU2830167C1 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
